Key result
A replication-defective human adenovirus (Ad5) vectored foot-and-mouth disease vaccine platform protects swine and cattle after a single immunization and has received a US conditional license.
This review outlines the development of an Ad5-vectored vaccine and biotherapeutics for foot-and-mouth disease in livestock, which has received a conditional license for the US National Veterinary Vaccine Stockpile.
We have developed a replication-defective human adenovirus (Ad5) vectored foot-and-mouth disease (FMD) vaccine platform that protects both swine and cattle from subsequent challenge with homologous virus after a single immunization. This Ad5-FMD vaccine has undergone testing following the requirements of the Center for Veterinary Biologics of the Animal Plant and Health Inspection Service, US Department of Agriculture, and has recently been granted a conditional license for inclusion of the vaccine in the US National Veterinary Vaccine Stockpile. In this review, we will describe the approaches we have taken to improve the potency and efficacy of this vaccine platform. Furthermore, we will discuss the development of Ad5 vector-based biotherapeutics to generate rapid protection against FMD virus prior to vaccine-induced adaptive immunity and describe the use of a combination of these approaches to stimulate both fast and long-lasting immunity.
No takes yet. Share an insight, caveat, or question.
Segundo et al. (2012) conducted a review in Foot-and-Mouth Disease. Replication-defective human adenovirus (Ad5) vectored foot-and-mouth disease (FMD) vaccine and biotherapeutics was evaluated. A replication-defective human adenovirus (Ad5) vectored foot-and-mouth disease vaccine platform protects swine and cattle after a single immunization and has received a US conditional license.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: